Arqam Zia, MD
Endocrinology, Diabetes & Metabolism · Canton, MINPI 1225028681
Payments from drug & device makers
Across 231 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$977
- Novo Nordisk$865
- Amgen$413
- Xeris Pharmaceuticals, Inc.$273
- Boehringer Ingelheim$211
- Abbott$173
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,69094%
- Education$2556%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 63 | $977 |
| Novo Nordisk | 63 | $865 |
| Amgen(2 entities) | 18 | $413 |
| Xeris Pharmaceuticals, Inc. | 14 | $273 |
| Boehringer Ingelheim | 13 | $211 |
| Abbott | 10 | $173 |
| Kyowa Kirin, Inc. | 2 | $135 |
| Mannkind Corporation | 6 | $123 |
| AstraZeneca | 9 | $119 |
| Radius Health, Inc. | 4 | $107 |
| Medtronic | 5 | $102 |
| Dexcom, Inc. | 4 | $75 |
| Insulet Corporation | 2 | $50 |
| Ascensia Diabetes Care US Inc. | 2 | $39 |
| Shire North American Group Inc | 2 | $37 |
| Halozyme Inc | 2 | $32 |
| Tandem Diabetes Care, Inc. | 2 | $30 |
| Sanofi-aventis U.S. LLC | 1 | $28 |
| Valeritas, Inc. | 1 | $24 |
| Amphastar Pharmaceuticals, Inc. | 1 | $22 |
| Recordati_rare_diseases_inc. | 1 | $20 |
| Sequel Med Tech, LLC | 1 | $17 |
| Gilead | 1 | $16 |
| BETA Bionics, Inc. | 1 | $16 |
| Ascendis Pharma Endocrinology Inc | 1 | $15 |
| Madrigal Pharmaceuticals | 1 | $14 |
| Cequr Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CRYSVITA$117
How this compares
$3,945 in reported general payments places this provider in the 60th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 323 | $463,920 |
| TrulicityDulaglutide | 157 | $262,256 |
| JardianceEmpagliflozin | 114 | $129,227 |
| FarxigaDapagliflozin Propanediol | 87 | $83,818 |
| JanuviaSitagliptin Phosphate | 37 | $42,578 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $31,799 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 220 | $28,726 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 55 | $24,131 |
| Gvoke Hypopen 2-PackGlucagon | 33 | $21,226 |
| Humalog Kwikpen U-100Insulin Lispro | 74 | $20,665 |
| Novolog FlexpenInsulin Aspart | 89 | $19,360 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 27 | $16,455 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $16,380 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 12 | $15,117 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 14 | $7,991 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $865 | $469,360349 claims |
| Lilly USA, LLCTrulicity, Humalog | $977 | $267,481180 claims |
| Boehringer IngelheimJardiance | $211 | $129,227114 claims |
| AstraZenecaFarxiga | $119 | $83,81887 claims |
| Sanofi-aventis U.S. LLCLantus | $28 | $1,28611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Canton
- Tobias ElseAnn Arbor$3.5M
- Elif OralAnn Arbor$2.9M
- Jamal HammoudFlint$2.6M
- Lowell SchmeltzFarmington Hills$2.3M
- George GrunbergerBloomfield Hills$1.9M
- Richard AuchusAnn Arbor$1.3M
- Ariel BarkanAnn Arbor$553K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Abdulsalam Al KassabRochester Hills$351K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.